Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

KYNMOBI for the Treatment of OFF episodes in Parkinson’s Disease

Drug Name

KYNMOBI™ (apomorphine hydrochloride)

Developer

Sunovion Pharmaceuticals

Therapy Class

Sublingual film

Product Description

Dopamine agonist

Current Indication

Parkinson’s disease

Market Sector

Central nervous system (CNS)

Development Status

Approved in Canada and the US
Expand
Close
Close
Close

Go Top